Business Wire·Aug 31, 2026, 6:00 PM ET

AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

AN2 Therapeutics announced four abstracts on epetraborole will be presented at the SOHO 2026 Annual Meeting in Houston from September 9-12, 2026.
The abstracts highlight potential beneficial effects of epetraborole on hematological profiles across clinical & nonclinical studies for polycythemia vera treatment.
Data demonstrates epetraborole's impact on erythropoiesis & hemoglobin-related parameters in healthy volunteers, non-PV patients, & nonhuman primate models.
Exposure-response relationships observed in nonhuman primates were predictive of effects subsequently seen in humans, supporting the translational relevance of these models.
Findings collectively support the ongoing clinical development of epetraborole as a novel oral boron-containing candidate for polycythemia vera.
The four presented abstracts cover exposure-dependent effects on erythropoiesis, safety profiles in non-PV populations, & exposure-response analyses in nonhuman primates.
Abstract copies are available on the AN2 Therapeutics website under the Presentations & Publications section.
AN2 Therapeutics is a clinical-stage biopharmaceutical company with three Phase 2 studies expected to be active in 2026 & a pipeline spanning hematologic, infectious, & oncology diseases.